LASA SUPERGENERICS

LASA SUPERGENERICS Q1FY21 PAT AT 5.37 CRS,
UP 437% YOY

Lasa Supergenerics Limited, a vertically integrated group spanning the entire animal and human healthcare value chain has announced its financial results for the first quarter ended June 30^th 2020 (Q1FY21)

 Q1FY21 performance overview compared with Q4FY20                                                                                                                                                                    

·         Revenues from operations stood at Rs. 54.60 crore as against Rs. 48.58 crore in Q4FY20

·         EBITDA of Rs. 12.20 crore as compared to Rs. 9.01 crore in Q4FY20

o   EBITDA margins at 22.34%

• PAT stood at Rs. 5.37 crore as compared to Rs.2.61 crore in Q4FY20

·         EPS for Q1FY21 stood at Rs. 1.32

 Q1FY21 performance overview compared with Q1FY20                                                                          

                                                                                               

·         Revenues from operations stood at Rs. 54.60 crore as against Rs. 38.98  crore in Q1FY20

·         EBITDA of Rs. 12.20 crore as compared to Rs. 5.06 crore in Q1FY20

o   EBITDA margins at 22.34% as against 12.98% in Q1FY20

• PAT stood at Rs.5.37 crore as against a loss of Rs.1.27 crore

·         EPS for Q1FY21 stood at Rs. 1.32 as compared to Rs. 0.47 in Q1FY20

For first quarter ended June 30^th 2020

• Revenues from operations for the first quarter ended June 30^th, 2020 (Q1FY21) stood at Rs. 54.60 crore.
  
  
• The Company reported Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) of Rs. 12.20 crore in Q1FY21, as against Rs 9.01 crore in Q4FY20; up 35.4%.
  The Company’s EBITDA margin stood at 22.34%
  
• The Company reported PAT of Rs. 5.37 crore for Q1FY21.The Company’s PAT margin stood at 9.84%
  
• Earnings per share (EPS) for the quarter ended Q1FY21 stood at Rs 1.32
  
• The Finance cost reduced by 45% Q-o-Q from Rs. 2.29 crore in Q4FY20 to Rs. 1.29 crore in Q1FY21

Commenting on the performance, Dr. Omkar Herlekar, Chairman – Lasa Supergenerics Limited, said,

“We have reported a good performance in our business in Q1 FY21 despite significant disruptions and ambiguity in the business environment. We are confident that the Company under its strong leadership and planned strategies will navigate through these difficult times. We have substantially brought down the debt.”

COVID 19: ICT, Lasa realise success in

COVID 19: ICT, Lasa realise success in Favipiravir drug synthesis, to commence production

Veterinary API Major, Lasa Supergenerics and Institute of Chemical Technology had come together in the month of March 2020 in effort to bring the antiviral to the market as a promising therapy to fight the ongoing Covid-19 pandemic.

Commenting on the development, Dr Omkar Herlekar, Chairman– Lasa Supergenerics Limited, said
Efforts over the last few months has brought success and we are looking to manufacture close to
10,000 doses to begin with and in the meanwhile also apply for the drug licence with competent
authorities and continue to seek strategic private investments or Government aid. Our move into
human steroid API is in line with the organisations inherent strengths and objectives to diversify.
Commenting on the antivirals successful synthesis, Prof. Vikas N Telvekar, ICT, Mumbai, said we
are happy to share with you that the Favipiravir molecule has been successfully synthesized in the
ICT laboratory on a lab scale and further pilot plan scale up is required.”

Recently in its Q4 results, the company reported a healthy increase in its PAT to Rs 3.63 cr for FY20,
as compared to a loss of Rs 12.04 cr in the corresponding period last fiscal
The stock ended at xxx high and xx low on June 17.